The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Staff & Volunteers
    • The Antibody Society’s Standing Committees
    • Advisors
    • Sponsors
    • James S. Huston Antibody Science Talent Award
  • Society meetings
    • Antibody Engineering & Therapeutics (US) 2020
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • Meeting reports
      • Keynote presentations
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2020
      • Antibody Engineering & Therapeutics Europe 2019
    • AIRR Community Meetings
    • FOCIS Symposia
    • Society-Funded Meetings
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Data Representation Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Minimal Standards Working Group
      • Software Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Antibodies in early-stage studies
    • Antibodies in late-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News You Should Know
    • Antibody therapeutics approved or in regulatory review in the EU or US
    • Research Resources
    • Education Resources
  • Career Center
  • Learning Center
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / About / Board of Directors / Sally Ward, Ph.D.

Sally Ward, Ph.D.

Prof. Sally Ward completed her graduate research in the laboratory of Professor David Ellar at the Department of Biochemistry, Cambridge University, Cambridge, U.K. She subsequently held a Research Fellowship at Gonville and Caius College whilst working in the same laboratory. From 1988 to 1990, she held the Stanley Elmore Senior Research Fellowship at Sidney Sussex College and carried out research related to antibody repertoire technology in Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology in Cambridge.

In 1990 she joined the University of Texas Southwestern Medical Center, Dallas, as an Assistant Professor. Since 2002, she was a Professor in the Department of Immunology at the same institution, and in 2004 was appointed to the Paul and Betty Meek-FINA Professorship in Molecular Immunology. In 2014 she moved as Professor to Texas A&M University Health Science Center. She was recently appointed as Professor in Molecular Immunology and Director of Translational Immunology in the Centre for Cancer Immunology at the University of Southampton.

Her research takes an interdisciplinary approach involving a combination of antibody/protein engineering, fluorescence imaging and in vivo studies to inform the design of antibody-based therapies for autoimmunity and cancer. The fluorescence microscopy and quantitative aspects of her work are carried out in collaboration with Professor Raimund Ober. In 1996, her laboratory identified the Fc receptor, FcRn, as a global regulator of IgG levels, leading to half-life extension and FcRn antagonist (Abdeg) technologies. These technologies have been licensed to biopharma, resulting in engineered, antibody-based therapeutics that are in Phase 2 or 3 clinical trials. Recent work in her laboratory has also described the generation of antibody-drug conjugates with engineered variable domains that have improved lysosomal delivery behavior. She serves on the editorial boards of mAbs and Protein Engineering, Design and Selection. In 2010, she was founding co-organizer of the Gordon Research Conference ‘Antibody Biology and Engineering’.

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Successful AIRR Community Meeting V January 15, 2021
  • Antibody Discovery in the Cloud: Using NGS to expand the universe of selectable antibodies January 13, 2021
  • AIRR Community and PrecisionFDA COVID-19 Precision Immunology App-a-thon December 28, 2020

Archives

Follow us online

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals